RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        GeneXpert MTB/RIF Testing in the Management of Patients with Active Tuberculosis; A Real Life Experience from Saudi Arabia

        Ali S. Omrani,Mohammed F. Al-Otaibi,Souad M. Al-Ateah,Fahad M. Al-Onazi,Kamran Baig,Noura A. El-Khizzi,Ali M. Albarrak 대한감염학회 2014 Infection and Chemotherapy Vol.46 No.1

        Background: GeneXpert MTB/RIF is a real-time PCR assay with established diagnostic performance in pulmonary and extra-pulmonaryforms of tuberculosis. The aim of this study was to assess the contribution of GeneXpert MTB/RIF assay to the management ofpatients with any form of active tuberculosis in a single large tertiary center in Saudi Arabia, with a special focus on the impact ontime to start of antituberculous therapy compared with Ziehl-Neelsen (ZN) smears and mycobacterial cultures. Materials and Methods: Clinical, radiological and laboratory records for all patients who were commenced on antituberculous therapybetween March 2011 and February 2013 were retrospectively reviewed. Results: A total of 140 patients were included, 38.6% of which had pulmonary tuberculosis. GeneXpert MTB/RIF was requested for only39.2% of patients and was the only reason for starting antituberculous therapy for only 12.1%. The median time to a positive GeneXpertMTB/RIF result was 0 days (IQR 3) compared with 0 day (IQR 1) for smear microscopy (P > 0.999) and 22 days (IQR 21) for mycobacterialcultures (P < 0.001). No patients discontinued antituberculous therapy because of a negative GeneXpert MTB/RIF result. Conclusions: In a setting wherein physicians are highly experienced in the diagnosis and treatment of tuberculosis, GeneXpertMTB/RIF was remarkably under-utilized and had only a limited impact on decisions related to starting or stopping antituberculoustherapy. Cost-effectiveness and clinical utility of routine testing of all smear-negative clinical samples submitted for tuberculosisinvestigations by GeneXpert MTB/RIF warrant further study.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼